Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Webinar: Prescription Rationale: Physician Research via an iPhone App

    September 18, 2013 | mobile research, prescription rationale, webinar 

    This webinar explores the potential of using smartphone Apps as a platform for collecting detailed qualitative insights into physicians’ decision rationale at the moment of prescription.

    Current statistics around mobile technology reveal that many physicians are now using iPhones, iPads and other mobile devices to assist them in their daily practices. Merck Serono and the Research Partnership’s paper used the findings from a study using mobile research technology in order to demonstrate how this methodology gives access to individual physicians’ thinking at the exact point when the decision to prescribe a brand is taken. Watch the webinar now to understand the many pros and cons of conducting mobile research, discover the value of mobile research and learn how mobile research can supplement existing research techniques.

    To view this webinar please visit: http://bit.ly/18yC1bA

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

    Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    How DataGateway unified oncology data for real-world insights & market intelligence

    Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

    Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    AI without limits: A smarter, integrated approach to Medical Affairs

    At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

    What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

    Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

    AI with intent: How Inizio is redefining pharma through precision and partnership

    At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

    Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

    Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.